Related Experiment Video

Updated: Mar 9, 2026

A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
07:14

A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation

Published on: July 13, 2018

15.4K

Effective Agents Targeting the Mitochondria and Apoptosis to Protect the Heart

Eltyeb Abdelwahid1, Aurimas Stulpinas2, Audrone Kalvelyte2

  • 1Feinberg School of Medicine, Feinberg Cardiovascular Research Institute, Northwestern University, 303 E. Chicago Ave., Chicago, IL, 60611. United States.

Current Pharmaceutical Design
|December 31, 2016
PubMed

Insights

Natural compounds protect heart cells by targeting mitochondria and apoptosis. These agents modulate mitogen-activated protein kinases (MAPKs), offering new avenues for cardiovascular disease treatment and drug discovery.

Area of Science:

  • Cardiovascular Medicine
  • Mitochondrial Biology
  • Cellular Apoptosis

Background:

  • Cardiovascular diseases involve cardiomyocyte mitochondria and apoptosis.
  • Mitochondrial dysfunction (decreased energy, altered redox, impaired calcium homeostasis) leads to cell death via the mitochondrial permeability transition pore (MPTP).
  • Mitochondrial signaling pathways are key targets for preventing and treating cardiovascular diseases.

Purpose of the Study:

  • To review the protective roles of agents, primarily natural compounds, in cardiovascular medicine.
  • To explore how these agents affect mitochondrial function and apoptosis.
  • To investigate the modulation of mitogen-activated protein kinases (MAPKs) by these compounds.

Main Methods:

  • Literature review of traditional and natural agents used in cardiovascular medicine.
  • Analysis of studies focusing on mitochondrial function and apoptotic pathways.
  • Examination of the role of mitogen-activated protein kinases (MAPKs) in mediating protective effects.

Main Results:

  • Various agents, especially natural compounds, demonstrate beneficial effects on mitochondrial function.
  • These agents can suspend apoptotic signaling mechanisms.
  • Modulation of mitogen-activated protein kinases (MAPKs) is a key mechanism of action.

Conclusions:

  • Mitochondrial signaling pathways are crucial targets for cardiovascular disease intervention.
  • Natural compounds show promise in protecting cardiomyocytes by improving mitochondrial function and inhibiting apoptosis.
  • Further research into cellular and molecular targets can inform future drug discovery and clinical applications for cardiovascular conditions.

Keywords:
Apoptosiscardioprotectiondrugsheartmitochondria

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K
Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

8.6K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453